HomeAI · summaries
Storia in 5 fonti
Jazz's HER2 bispecific Ziihera gains FDA approval to change practice in stomach cancer
Jazz Pharmaceuticals’ bispecific antibody Ziihera has gained FDA approval for first-line HER2-positive stomach cancer, unlocking another market as the company builds toward a $2 billion-plus peak s | Jazz’s bispecific antibody Ziihera has gained FDA approval for first-line HER2-positive stomach cancer, unlocking another market as the company builds toward a $2 billion-plus peak sales target.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Ziihera combinations for gastroesophageal adenocarcinoma
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal…
- ·
biopharmadive.com
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
